Bispecific antibodies in cancer immunotherapy

Therapeutic Advances in Vaccines and Immunotherapy
Eva DahlénPer Norlén

Abstract

Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeutic bispecific antibodies: (a) cytotoxic effector cell redirectors; (b) tumor-targeted immunomodulators; and (c) dual immunomodulators. Cytotoxic effector cell redirectors are dominated by T-cell redirecting compounds, bispecific compounds engaging a tumor-associated antigen and the T-cell receptor/CD3 complex, thereby redirecting T-cell cytotoxicity to malignant cells. This is the most established class of bispecific immunotherapies, with two compounds having reached the market and numerous compounds in clinical development. Tumor-targeted immunomodulators are bispecific compounds binding to a tumor-associated antigen and an immunomodulating receptor, such as CD40 or 4-1BB. Such compounds are usually designed to be inactive until binding the tumor antigen, thereby localizing immune stimulation to the tumor environment, while minimizing immune activation elsewhere. This is expected to induce powerful activation of tumor-specific T ce...Continue Reading

References

Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Torsten DreierPatrick A Baeuerle
Oct 23, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hyeon-Woo LeeByoung S Kwon
Feb 3, 2005·International Journal of Cancer. Journal International Du Cancer·Patrick HoffmannPatrick A Baeuerle
Feb 24, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gayle PulleTania H Watts
Jul 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander BurgesRainer Kimmig
Mar 2, 2010·MAbs·Rolf LinkeDiane Seimetz
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Ralf LutterbuesePeter Kufer
Jul 16, 2010·Immunology and Cell Biology·Connie JackamanDelia Jane Nelson
Sep 8, 2010·The Journal of Experimental Medicine·Kaori SakuishiAna C Anderson
Jun 28, 2011·International Journal of Cancer. Journal International Du Cancer·Marion G OttDiane Seimetz
Mar 31, 2012·Nature Reviews. Drug Discovery·P Mark Hogarth, Geoffrey A Pietersz
May 9, 2012·Nature Medicine·Nathaniel LiddyBent K Jakobsen
Jul 19, 2012·International Reviews of Immunology·Andrea KhongBruce W S Robinson
Aug 4, 2012·International Journal of Cancer. Journal International Du Cancer·Marieke F FransenCornelis J M Melief
Mar 6, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert H Vonderheide, Martin J Glennie
May 30, 2013·Cancer Immunology, Immunotherapy : CII·Nora HornigDafne Müller
Sep 21, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Qunrui YeDaniel J Powell
Jan 15, 2014·Cancer Immunology Research·Lee P Richman, Robert H Vonderheide
Jul 16, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ann L WhiteStephen A Beers
Oct 16, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sara M MangsboPeter Ellmark
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Nov 5, 2014·Immunology and Cell Biology·Amelia M HuehlsCharles L Sentman
Nov 5, 2014·Frontiers in Immunology·Gestur VidarssonTheo Rispens
Nov 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Max S ToppRalf C Bargou
Dec 3, 2014·Pharmacology & Therapeutics·Cindy NeuzilletArmand de Gramont
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfJedd D Wolchok
Feb 24, 2015·Frontiers in Immunology·Nathan C Horton, Porunelloor A Mathew

❮ Previous
Next ❯

Citations

Jan 27, 2019·American Journal of Hematology·Steven FeinsJoseph A Fraietta
May 18, 2019·American Society of Clinical Oncology Educational Book·Charlene M FaresSiwen Hu-Lieskovan
Apr 3, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Marra, G Curigliano
Jul 30, 2019·Immunological Reviews·Breelyn A Wilky
Nov 13, 2019·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·Johannes Wohlrab
Mar 4, 2020·Cells·Andrew M K LawDavid Gallego-Ortega
Apr 16, 2020·Current Protocols in Immunology·Ling HuangGundo Diedrich
Jul 6, 2019·ESMO Open·Alex FriedlaenderGiuseppe Banna
Jun 25, 2020·Clinical Pharmacology and Therapeutics·Alison Betts, Piet H van der Graaf
Sep 23, 2020·Pharmaceutical Patent Analyst·Martin Perez-Santos
Oct 2, 2019·Clinical & Translational Immunology·William C DougallMark J Smyth
May 12, 2020·Frontiers in Immunology·Chiara CaraccioChristian M Schürch
Jun 12, 2020·Therapeutic Advances in Hematology·Jose-Maria RiberaJordi Ribera
May 14, 2020·Nature Reviews. Clinical Oncology·Won Jin HoLei Zheng
Mar 20, 2019·Journal of Immunology Research·Shixue ChenLei Zhao
Jun 25, 2019·Expert Opinion on Investigational Drugs·Andrea GombosAhmad Awada
Aug 14, 2019·Human Vaccines & Immunotherapeutics·David M RichardsChristian Merz
Aug 23, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Bushra Husain, Diego Ellerman
Nov 17, 2020·Frontiers in Oncology·Fen WangQing Zhou
Nov 27, 2020·Proceedings of the National Academy of Sciences of the United States of America·Jacqueline MockDario Neri
Dec 5, 2018·Cancer Immunology Research·Arabella YoungJeffrey A Bluestone
Sep 3, 2020·Cancer Immunology Research·Helen KotanidesMichael Kalos
Jul 1, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Javier Martín-BrotoBrian A Van Tine
Dec 11, 2020·European Journal of Immunology·Sundee DeesIqbal S Grewal
Sep 22, 2020·Panminerva Medica·Yunxin ChenClaudio Cerchione
Jan 4, 2021·Trends in Cell Biology·Martina KreilederWalter Kolch
Jan 21, 2021·Cancers·Jim MiddelburgThorbald van Hall
Feb 21, 2021·Journal for Immunotherapy of Cancer·Jason J LukeLawrence Fong

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01741792
NCT02811679
NCT03173430
NCT02699515
NCT02517398
NCT03219268

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.